Cost of treatment

I don’t think this will surprise you. Multiple sclerosis drugs, some of the most expensive drugs there are, are getting even more expensive. Drug industry analyst Eric Schmidt, quoted in the Boston Business Journal, reported that Biogen began the new year by upping the price of Tecfidera,…

A cost-effectiveness analysis of reimbursement recommendations for four relatively new multiple sclerosis (MS) treatments made by agencies in four countries — Australia, Canada, Sweden, and the U.K. — found overwhelming support (88 percent) for either full or restricted reimbursement for each therapy. The analysis, performed by the Decision Resources Group, is…

“… in 3 years we went from living decent not rich to poverty and will prob have no utilities soon and maybe homeless.” An MS patient wrote that after I posted Part I of this column a few days ago. “I went threw (sic) all of our savings…

I’m not asking for your money.  (At least not yet.)  But I’ve recently seen a lot of news stories about MS patients who are. Multiple sclerosis battler fights for $200,000 treatment Or… Fundraiser for Deanna Or… Burbage dad’s £50,000 appeal to…

It’s that time of the year. Drug insurance companies in the U.S. are making changes to their formularies — the list of drugs that your insurance company will pay for. Those formularies change from year to year so you need to be alert to changes that may impact your…

The National Multiple Sclerosis Society has launched an initiative, called Make MS Medications Accessible, calling for change in the pricing of multiple sclerosis (MS) medications in the U.S., which the group said need to be more affordable, and ways of acquiring them more simple and transparent. The initiative asks leaders of all…

If only we were cherub faced children, then perhaps someone would have listened to us in the past few years as we voiced concern and then outrage over the escalating costs of our MS disease modifying therapy (DMT) drugs. I’ve listened to the outcry in recent weeks about the astronomical…

In a session titled “Challenges for care and research in MS outside Europe and North America” at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress Sept. 14-17 in London, researchers from Latin America shared the obstacles of scientists and multiple sclerosis (MS) patients in the…

At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking place in London on Sept. 14–17, Biogen will present the Multiple Sclerosis Cost of Illness study, based on research into more than 16,000 MS patients throughout Europe. The study builds on data from a leading 2005 study that…

Anyone with a chronic medical problem knows how expensive drugs can be, and how a drug that you need can be here today … gone tomorrow on the list of drugs that your health plan will pay for. You also know that cost and insurance coverage aren’t the only…

Virtually all the talk about availability of HSCT1 as an MS treatment includes the need to travel long distances to other countries, but U.K. residents can receive the treatment in London, avoiding the journey overseas. What’s more, it is provided through the country’s social National Health Service (NHS) so, like…

The CVS Caremark covered insurance plan has dropped Avonex, Plegridy and Extavia, three multiple sclerosis disease-modifying therapies, from their 2017 formulary. You say, OK, but what does that really mean? If your prescription insurance is through CVS Caremark, and you want one of those drugs or one…

  We may have international cooperation and worldwide this and that, but the fact remains that countries vary drastically from one another in all sorts of ways. Take healthcare as an example, and the costs of treatment. Yes, we have the World Health Organization and there are various health-related initiatives…

Multiple sclerosis (MS) patients in the U.S. with higher disability scores also have higher rates of health resource utilization, higher healthcare costs, and lower work productivity and health-related quality of live, according a study by researchers at Adelphi Real World and Abbvie. The study, “Quantifying the…

A recent survey of more than 6,000 multiple sclerosis patients in the United States found that health insurance coverage can decide their access to disease-modifying therapies (DMTs), and that that coverage is worsening, leaving a good number struggling to be able to pay for their treatment. As an MS patient myself, I find…

Individual health insurance coverage largely determines a multiple sclerosis (MS) patient’s access to disease modifying drugs in the United States, mainly because of the rising costs of newer medications and near-annual changes in insurance policy coverage, usually making such coverage more restrictive, researchers report.  These twin problems often leave MS patients relying on suboptimal therapies rather than those…

A recent study analyzing the healthcare resource use and cost of H.P. Acthar Gel, an injectable drug used to manage multiple sclerosis (MS) relapse, demonstrated that the therapy is a viable alternative to plasmapheresis (PMP) and intravenous immunoglobin (IVIG). Annual direct healthcare costs encountered by MS patients in the U.S.

Clinical results presented at the recent Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meeting in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses is associated with beneficial outcomes. The gel, according to its producer, is also available at a lower price than other frequently used…

The Co-Pay Relief program offered through the Patient Advocate Foundation has added a new financial assistance fund to its collection of resources for patients with multiple sclerosis (MS). The new fund is now available to financially eligible MS patients with health insurance coverage to support the costs of necessary treatment medicines. “Our case management department has been…

A new report, written jointly by the NHiS Commissioning Excellence and the Multiple Sclerosis (MS) Trust, highlights the healthcare costs of emergency hospitalization of MS patients in the United Kingdom and points to more cost-effective and better ways to care for this patient population. The executive summary and full report are…

Researchers at Oregon Health & Science University (OHSU) College of Pharmacy and Oregon State University (OSU) at Corvallis, and Veterans Affairs Medical Center in Portland, Oregon, have documented an “alarming rise” over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis…

The Austrian Centre of Industrial Biotechnology (acib) developed a new purification method for pharmaceutical produced antibodies that promises to effectively decrease the high prices of these drugs in the market. Therapeutic antibodies revolutionized how doctors treat diseases affecting a large number of individuals, such as cancer and autoimmune…

Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drug Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…

The Pharmaceutical Management Agency (PHARMAC) is considering a funding proposal that includes five treatments for multiple sclerosis (MS), namely two key MS drugs,  Biogen‘s Tysabri and Novartis‘ Gilenya, that are not currently funded. PHARMAC is the New Zealand Crown agency that decides, on behalf of District…

The main costs of care for multiple sclerosis (MS) patients continue to be driven predominantly by common MS “sequelae” — a condition that is the consequence of a previous disease or injury — according to a recent study from the BMC Health Services Research. However, in spite of cost drivers remaining steady,…